Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pelthos Therapeutics ( (PTHS) ) is now available.
Pelthos Therapeutics reported its financial results for the second quarter of 2025, marking the last report for legacy operations before its merger with Channel Therapeutics Corporation on July 1, 2025. The company has launched ZELSUVMI, a novel treatment for molluscum contagiosum, and completed the build-out of its management and sales teams, positioning itself for growth. The merger and a $50.1 million private placement financing are expected to support the commercial launch of ZELSUVMI and expand Pelthos’ market presence.
The most recent analyst rating on (PTHS) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
More about Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company focused on commercializing innovative therapeutic products to address high unmet patient needs. The company’s lead product is ZELSUVMI™ (berdazimer) topical gel, 10.3%, which is the first FDA-approved at-home treatment for molluscum contagiosum.
Average Trading Volume: 62,010
Technical Sentiment Signal: Strong Buy
For a thorough assessment of PTHS stock, go to TipRanks’ Stock Analysis page.